CN117597367A - 血管性血友病因子(vwf)抑制剂 - Google Patents

血管性血友病因子(vwf)抑制剂 Download PDF

Info

Publication number
CN117597367A
CN117597367A CN202280030093.5A CN202280030093A CN117597367A CN 117597367 A CN117597367 A CN 117597367A CN 202280030093 A CN202280030093 A CN 202280030093A CN 117597367 A CN117597367 A CN 117597367A
Authority
CN
China
Prior art keywords
seq
antibody
chain variable
binding fragment
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280030093.5A
Other languages
English (en)
Chinese (zh)
Inventor
纳丁·克莱蒙
艾伦·刘易斯
汤姆·麦金农
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2 Ipo Innovation Co ltd
Original Assignee
Ip2 Ipo Innovation Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ip2 Ipo Innovation Co ltd filed Critical Ip2 Ipo Innovation Co ltd
Publication of CN117597367A publication Critical patent/CN117597367A/zh
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71Decreased effector function due to an Fc-modification
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/11Antisense
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering nucleic acids [NA]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745Assays involving non-enzymic blood coagulation factors
    • G01N2333/755Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280030093.5A 2021-04-20 2022-04-20 血管性血友病因子(vwf)抑制剂 Pending CN117597367A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2105625.4A GB202105625D0 (en) 2021-04-20 2021-04-20 Von willebrand factor (VWF) inhibitors
GB2105625.4 2021-04-20
PCT/GB2022/050989 WO2022223966A1 (en) 2021-04-20 2022-04-20 Von willebrand factor (vwf) inhibitors

Publications (1)

Publication Number Publication Date
CN117597367A true CN117597367A (zh) 2024-02-23

Family

ID=76377797

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280030093.5A Pending CN117597367A (zh) 2021-04-20 2022-04-20 血管性血友病因子(vwf)抑制剂

Country Status (12)

Country Link
US (1) US20240228660A1 (https=)
EP (1) EP4326778A1 (https=)
JP (1) JP2024514708A (https=)
KR (1) KR20240004332A (https=)
CN (1) CN117597367A (https=)
AU (1) AU2022262695A1 (https=)
BR (1) BR112023021631A2 (https=)
CA (1) CA3214716A1 (https=)
GB (1) GB202105625D0 (https=)
IL (1) IL307441A (https=)
MX (1) MX2023012391A (https=)
WO (1) WO2022223966A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202215432D0 (en) * 2022-10-19 2022-11-30 Ip2Ipo Innovations Ltd Von Willebrand factor (VWF) antibody

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
EP2543678A1 (en) * 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the treatment and prevention of thrombosis

Also Published As

Publication number Publication date
JP2024514708A (ja) 2024-04-02
US20240228660A1 (en) 2024-07-11
MX2023012391A (es) 2024-02-02
KR20240004332A (ko) 2024-01-11
IL307441A (en) 2023-12-01
EP4326778A1 (en) 2024-02-28
WO2022223966A1 (en) 2022-10-27
CA3214716A1 (en) 2022-10-27
GB202105625D0 (en) 2021-06-02
AU2022262695A1 (en) 2023-10-05
BR112023021631A2 (pt) 2024-02-27

Similar Documents

Publication Publication Date Title
KR102924006B1 (ko) 항-pd-l1/항-4-1bb 이중특이적 항체 및 이의 용도
KR102540192B1 (ko) Cd123 결합제 및 그의 용도
CN108064236B (zh) 新颖的il33形式、il33的突变形式、抗体、测定及其使用方法
EP3936526A1 (en) Bifunctional fusion protein and pharmaceutical use thereof
CN112566662A (zh) 针对cd47的阻断抗体及其使用方法
CN113248618B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
TW201132353A (en) WISE binding agents and epitopes
CN110678484B (zh) 抗pd-l1/抗lag3双特异性抗体及其用途
CN111196854A (zh) Ox40抗体及其制备方法和应用
US11542329B2 (en) Antibodies targeting Glycoprotein VI
US20230357387A1 (en) Zip12 antibody
AU2018214222C1 (en) Inhibition of platelet aggregation using anti-human GPVI antibodies
CN117597367A (zh) 血管性血友病因子(vwf)抑制剂
WO2024084214A1 (en) Von willebrand factor (vwf) antibody
US20250277038A1 (en) Anti-pd-l1 antibody and use thereof
HK40057471B (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof
HK40057471A (en) Anti-pd-l1/anti-lag3 bispecific antibody and use thereof
WO2026017189A2 (zh) 抗il-31抗体、其药物组合物及用途
KR20240162566A (ko) Zip12 항체
WO2025172587A1 (en) Binding constructs
WO2025256571A1 (zh) 靶向b7h7和cd3的双特异性抗体及其应用
HK40019833A (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
HK40077561A (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
HK40019833B (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
KR20200119846A (ko) 항 비7 에이치4 항체, 그의 항원 결합 단편 및 그의 약학적 용도

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination